Oncology Institute (TOI) reported a Q4 loss late Thursday of $0.06 per diluted share, narrowing from the loss of $0.14 a year earlier.
Four analysts polled by FactSet expected a loss of $0.09.
Revenue for the three months ended Dec. 31 rose to $142 million from $100.3 million a year earlier.
Four analysts expected $139.8 million.
The company expects full-year 2026 revenue of $630 million to $650 million.
Four analysts project $636.2 million.
Oncology Institute shares rose 13% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments